NCT05472324View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

PHASE2UnknownINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Severe Asthma
Interventions
DRUG

TQC2731 injection

TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.

DRUG

Placebo

The drug is a placebo Comparator.

Trial Locations (2)

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510180

RECRUITING

GUANGZHOU FIRST PEOPLE's HOSPITAL, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY